A Non-randomised, Open-label Phase I Trial to Evaluate the Effect of BI 456906 at Different Dose Levels of Multiple Subcutaneous Doses in a Titration Scheme on the Single Dose Pharmacokinetics of a Combination of Ethinylestradiol and Levonorgestrel in Otherwise Healthy Women With Overweight/Obesity
Latest Information Update: 16 Apr 2025
At a glance
- Drugs Ethinylestradiol/levonorgestrel (Primary) ; Survodutide (Primary)
- Indications Non-alcoholic steatohepatitis; Obesity; Pregnancy; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
Most Recent Events
- 11 Apr 2025 Status changed from active, no longer recruiting to completed.
- 14 Nov 2024 Planned primary completion date changed from 26 Mar 2025 to 12 Feb 2025.
- 19 Sep 2024 Status changed from recruiting to active, no longer recruiting.